ID-Tag RVP In Agreement with Current Testing Methods

Bioscience Corp., a leader in the commercial genetic testing market, has announced results from the North American arm of its clinical trial for the ID-Tag Respiratory Viral Panel (RVP), a proprietary, comprehensive test for the detection of the majority of strains and subtypes of respiratory viruses, including respiratory syncytial virus (RSV) A and B, influenza A (with subtyping) and influenza B.
The North American results show an overall 98.5 percent agreement between the ID-Tag RVP and the current standard for testing, direct fluorescent antibody (DFA) combined with cell culture. This agreement is based on comparing 4,460 results generated from patient samples by the multiplexed RVP assay for which the presence or absence of a particular virus was established either by DFA or cell culture. Current DFA/culture algorithms used in routine diagnostic testing may take 2 to 10 days to generate a result for only a subset of the targets studied in this trial. The ID-Tag RVP assay provides a result in six hours.